16:55 , Jan 12, 2018 |  BC Week In Review  |  Company News

Exelixis, StemSynergy in CSNK1A activator deal

Exelixis Inc. (NASDAQ:EXEL) and StemSynergy Therapeutics Inc. (Miami, Fla.) partnered to discover and develop compounds targeting casein kinase 1 alpha (CSNK1A; CKI-alpha) to treat cancer. The partners will conduct preclinical and clinical studies of compounds from...
21:00 , Aug 17, 2017 |  BC Innovations  |  Translation in Brief

Stopping the invasion

A team from the Netherlands Cancer Institute (NKI) has identified a network of extracellular matrix proteins that drives glioblastoma invasiveness and a master switch -- interferon regulatory factor 3 (IRF3) -- that can turn it...
17:44 , Aug 16, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Cell culture studies suggest activating IRF3 or inhibiting its negative regulator CSNK2 could help treat glioblastoma multiforme (GBM). In mouse brain slices co-cultured with a patient-derived GBM cell line, vector-mediated constitutively active IRF3...
21:05 , Jul 18, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Patient sample, in vitro, cell culture and mouse studies identified a benzamide-based CSNK1A activator that could help treat Wnt signaling-driven colorectal cancer. In colorectal cancer patients, low tumor levels of CSNK1A were associated...
23:53 , Feb 28, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Huntington's disease (HD) Patient sample and mouse studies suggest inhibiting CSNK2A2 could help treat HD. Levels of CSNK2A2 were higher in striatal tissue samples from HD patients and striatal and gastrocnemius muscle tissue samples from...
07:00 , Aug 4, 2016 |  BC Innovations  |  Targets & Mechanisms

Cereblon ambition

Most anti-cancer strategies aim to block overactive proteins by directly inhibiting their activity, but a growing number of companies are developing ways to tag the proteins for destruction by recruiting the enzymes that shuttle them...
07:00 , May 16, 2016 |  BC Week In Review  |  Company News

Hebrew University of Jerusalem, BioTheryX deal

The university’s Yissum Research Development Co. and BioTheryX partnered to develop and commercialize casein kinase 1 alpha ( CSNK1A; CKI-alpha) inhibitors to treat hematologic and solid malignancies. The collaboration will initially focus on...
07:00 , Apr 16, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Casein kinase 1α (CSNK1A; CK1-α)

Cancer INDICATION: Cancer In vitro and mouse studies suggest inhibiting CSNK1A and autophagy could help treat cancers expressing oncogenic Ras. In Ras-expressing human fibroblasts and colon cancer cells, siRNA targeting CSNK1A or a small molecule CSNK1A inhibitor...
07:00 , Oct 23, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Myelodysplastic syndrome (MDS) Casein kinase 1 (CSNK1; CKI) In vitro and mouse studies suggest inhibiting CSNK1 could...
07:00 , Aug 28, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Casein kinase 1a (CSNK1A; CKI-a); sonic hedgehog homolog (SHH) Mouse and cell culture studies suggest...